EU Launches Joint Assessment Of Pediatric & Orphan Drugs Legislation
Executive Summary
A new European Commission consultation marks the launch of an evaluation exercise to assess the joint impact of the EU pediatric and orphan drugs legislation in supporting the development of pediatric medicines for rare diseases.
You may also be interested in...
Keep It Simple: EU Consults On Future Design Of EMA’s Fee System
Following a report that identified several shortcomings of the European Medicines Agency fee system, the European Commission has suggested various options to make it sustainable and future-proof.
European Commission Continues With Mission To Assess Impact of Orphan Regulation
Companies now have a chance to have their say about their experience of EU Orphan Drug Regulation.
Combined Effect Of EU Pediatrics And Orphan Drugs Legislation Under EU Commission Scrutiny
A joint evaluation of the EU pediatrics and orphan drugs legislation is due to commence next year in an effort to understand why the two legal instruments have failed to encourage companies to develop medicines targeting rare diseases in children. The initiative will help decide the possible need for future changes.